by
Thomas Dworetzky, Contributing Reporter | October 12, 2015
“[The Nestlé facility] is really going to make it an area for innovation,” she said. “It’s a great New Jersey story and it shows that we are able to reinvent ourselves in a space that was huge, and now we’ve been able to develop it in a way — working together with [owners Advance Realty and CrossHarbor Capital Partners] — to make it a destination for life sciences.”
Nestlé Health Sciences has been in the news recently with a number of other deals. In September it entered into a deal for exclusive rights to Lipid Therapeutics' LT-02 compound (phosphatidylcholine), a novel barrier function therapy for patients with mild-to-moderate ulcerative colitis (UC), worldwide excluding Europe and Australia.
In addition, The Nestlé Institute of Health Sciences SA signed a research collaboration agreement in September with AC Immune SA to develop a sensitive, minimally invasive Tau diagnostic assay for early Alzheimer's disease using Nestlé's proprietary multiplexed ultrasensitive antibody technology platform.
Back to HCB News
